Atara Biotherapeutics, Inc.
ATRA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$8.35
KIRA · Stoqly’s AI analyst, in plain words
- Atara Biotherapeutics, Inc. had $121M of revenue in fiscal 2025, down 6.3% on the year before.
- Its operating margin was 29.7%, up 94.4 pts: of every 100 in sales, about 30 is left after running the business.
- Atara Biotherapeutics, Inc. made $32.7M of net profit in fiscal 2025.
- Free cash flow was −$50.9M in fiscal 2025, −42.2% of revenue.
Market cap
$126M
P/E
—
Revenue
$121M
Net income
$32.7M
Free cash flow
−$50.9M
Operating margin
29.7%
Atara Biotherapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−6.3%
No. Sales fell 6.3% last year.
Does it make a profit?
27.1%
Yes. It keeps 27.1% of every sale as profit.
Does profit turn into cash?
−42.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Atara Biotherapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Atara Biotherapeutics, Inc.
- CIK
- 0001604464
Atara Biotherapeutics, Inc. · ATRA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $63.6M | $8.6M | $129M | $121M |
| Revenue growth | — | — | −86.5% | 1,404.0% | −6.3% |
| Operating margin | — | −441.2% | −3,219.5% | −64.7% | 29.7% |
| Net income | −$340M | −$228M | −$276M | −$85.4M | $32.7M |
| Net margin | — | −359.1% | −3,220.9% | −66.2% | 27.1% |
| Diluted EPS | −$3.63 | −$2.24 | −$65.19 | −$11.41 | $2.57 |
| Cash | |||||
| Cash from operations | −$221M | −$270M | −$193M | −$68.7M | −$50.9M |
| Capital expenditure | $10.6M | $4.2M | $1.2M | $0.2M | $0.0M |
| Free cash flow | −$231M | −$275M | −$194M | −$69.0M | −$50.9M |
| FCF margin | — | −432.0% | −2,265.3% | −53.5% | −42.2% |
| Share count change | 26.6% | 8.9% | −95.8% | 76.8% | 69.8% |
| Debt and strength | |||||
| Cash and short-term investments | $371M | $243M | $51.7M | $42.5M | $8.5M |
| Shareholders' equity | $280M | $127M | $99.2M | −$97.3M | −$38.5M |
| Current ratio | 3.6x | 3.7x | 0.7x | 0.5x | 0.8x |
| Interest coverage | — | −752.0x | −52.2x | −18.1x | 9.5x |
| Returns and quality | |||||
| Return on equity | −91.7% | −112.4% | −244.5% | −8,768.3% | — |
| Return on tangible equity | −121.6% | −180.3% | −278.3% | — | — |
| Piotroski F-score | — | — | 2 | 3 | 4 |
| Altman Z'' | −9.6 | −15.4 | −51.2 | −71.2 | −315.4 |
Insiders bought, 12 months
$5.7M
2 insiders
Insiders sold, 12 months
$3.9M
4 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Atara Biotherapeutics, Inc. · ATRA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.35 a share, the company is worth $126M.
Source: SEC EDGAR XBRL filings (CIK 0001604464). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.